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Introduction
Thalassemia syndromes are a heterogeneous group
of disorders characterized by a lack or decreased synthesis
of either alpha or beta chains of haemoglobin. Beta
thalassemia is the most common haemoglobinopathy in
Pakistan.1
The management of Thalassemia Major in most of
the patients in our country is with blood transfusions and
iron chelation therapy. However most of these patients
develop progressive iron overload that is responsible for
tissue damage and eventually death.2
Traditionally Desferrioxamine was administered to
the patients for iron chelation as a subcutaneous infusion
given over 8-12 hours, 5-7 days a week with a pump. This
was a cumbersome mode of administration with pain at site
and low compliance of the patients.
Deferiprone (Kelfer, Ferriprox) is an orally active
hydroxypyridineone first used in humans in 1987.3 It is a
tridentate chelator i.e. three molecules surround one iron
ion; carries no net charge and can easily penetrate
membranes. Due to oral mode of administration the
compliance is better.4
A study was therefore conducted to determine the
efficacy, safety and adverse effects of oral iron chelator
Deferiprone in patients with Thalassemia major.
Patients and Methods
This study was conducted at Fatimid foundation
blood bank and haematological diseases center Lahore from
September 2005 till November 2006.
A total of 87 patients were included in the study.
From the diagnosed cases of Thalassemia major with
more than twenty blood transfusions, only those were
included who had serum Ferritin levels more than 1000
ng/ml. The baseline physical and clinical examination
findings along with laboratory data were recorded on a
questionnaire.
They were followed up for a minimum of two
months. Deferiprone was given seven days a week at a dose
of 75mg/kg/ day in two to three divided doses.
The patients were followed up for a period of one
year. Complete blood count was performed every two
weeks and on the day of the transfusion in all patients for
the duration of the study period. Adverse events were
recorded on the patient Performa and also recorded in the
patients files. The primary outcome variable was serum
Ferritin level at the start and at the end of study. A p-value
of <0.05 was considered statistically significant.
Patients who had poor compliance and follow up
were excluded from the study.
Serum Ferritin level was carried out by microparticle
enzyme linked immunoassay on kits manufactured by
Abbott Laboratories USA on Axsym automated analyzer.
ECG, Echocardiography and Magnetic Resonance
Imaging could not be performed due to economic
constraints.
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Abstract
Objective: To determine the efficacy and adverse effects of deferiprone in patients with Thalassemia Major.
Methods: A prospective case series study was conducted at the Fatimid Foundation Blood Bank and
Haematological Diseases center Lahore. A total of 87 patients entered into the study between September 2005
and November 2006. Deferiprone was given at subsidized rates at a dose of 75/mg/day for seven days. Physical
examination and initial Laboratory investigations were done in all patients at the start of the study. Physical and
laboratory data were filled on a questionnaire and analyzed using SPSS version10.0.
Results: Eighty seven patients with mean age of 10.0 ± 4.33 years (range 4-27 years) were included in the study.
Mean follow up was 8 ± 3.94 months (range 2-12 months). The mean Ferritin at the start of study was 4656 ± 2052.5
ug/L (range 1200-14630 ug/L) and at the end of study period was 4139 ± 1710.4 ug /L (range 749-8961) (p < 0.001).
Adverse events were joint pains in 10 % patients, gastrointestinal symptoms in 11% and no adverse events in
79 % patients. There was no evidence of agranulocytosis in any patient.
Conclusion: Deferiprone was well tolerated, had few adverse effects and was effective in lowering the patient's
serum ferritin level (JPMA 59:388; 2009).
All the data was entered and analyzed using SPSS
(statistical package for social sciences) version 10.0.
Descriptive statistics were expressed in the form of range,
mean ± one standard deviation (SD). Student t test was
applied to compare means of Ferritin at the start and end of
study period.
Results
A total of 87 patients were included in the study.
Mean age of the patients was 10.0 ± 4.33 years (range 4-24
years). Gender distribution showed that 58 (66.6 %) were
male and 29 (33.3 %) were female. Mean follow up was 8
±3.94 months (range 2-12 months). 
The mean Ferritin at the start of study was 4656 ±
2052.5 ng/ml (range 1200-14630 ng/ml) and the mean
Ferritin at the end of study period was 4139 ± 1710.4 ng/ml
(range 749-8961 ng/ml) p < 0.001.
The most common adverse reactions observed
during the study comprised of nausea, vomiting and
abdominal pain. Nine (11%) of the patients reported these
symptoms; however no interruption of therapy or decrease
in dosage was necessitated because of these symptoms.
None of the patients discontinued therapy because of
gastrointestinal adverse effects. Agranulocytosis was not
seen in any of the patients.
Bone pain and arthropathy was the most common
complaint encountered in 8 (10%) patients, necessitating
decrease in dosage or stoppage of therapy. The bone pain
and swelling subsided in seven out of eight patients
subsequent to stoppage of therapy with Deferiprone and
these patients were then continued on Desferrixoamine.
Patients not experiencing any adverse effect were 68
(79%). No patient died during the course of the study and
no patient developed the clinical findings of congestive
heart failure. 
Discussion
To our knowledge, this is the largest study to date
from Pakistan detailing Deferiprone administration and
monitoring of adverse reactions in patients with
Thalassemia major.
The results are indicative of good efficacy of
Deferiprone in lowering patients' serum Ferritin level and
low frequency of adverse reactions.
Ayyub et al2 demonstrated good efficacy of the oral
iron chelator over a 3.8 year study period with significant
reduction in Ferritin, good compliance and acceptable
safety profile. Gastrointestinal disturbances and
Arthropathy were significant adverse effects with oral iron
chelator and are comparable to our study. 
Another study from India reported an increase in
ferritin levels in the oral Deferiprone group but a decrease
in Ferritin levels in the combination of Deferiprone and
Deferrioxamine in patients with Thalassemia major.4
Arthropathy was a significant side effect with Deferiprone
in this study too.
In a meta-analytic review published in 1999,5 the
authors had confirmed the efficacy of Deferiprone which is
comparable to the results of the presented study. 
The adverse reactions profile was also similar to
other studies.2,3,6 The two most important observations were
non-occurance of agranulocytosis in any of the patients who
were administered this drug. Bone pain and arthropathy was
found to be the most side effect which led to dose reduction
and/or stoppage of therapy in these patients.
Non-compliance was also found to be a major factor
while administering the drug. Although most of the patients
were receiving the drug at subsidized rates, still about 19 %
were unable to take the drug on a regular basis because of
economic reasons. These were excluded from the final
analysis.
Gastrointestinal symptoms were reported to be the
most common symptoms associated with Deferiprone
therapy by Cohen et al.7 They found joint problems in 15%
of the patients over a period of four years. 
A latest literature review suggests that Deferiprone is
not an alternative to Desferrioxamine and should be used in
conjunction with Desferrioxamine for more effective iron
chelation therapy.8
Conclusion
In this study Deferiprone was well tolerated, had few
adverse effects and was effective in lowering the serum
Ferritin level in patients with Thallasaemia Major. 
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